As popular as Botox Cosmetic Injections are, it is surprising that it has taken so long for competing products to appear on the market. Compared to the number of hyaluronic acid-based injectable facial fillers (like Juvéderm), the monopoly of Botox on the muscle relaxant injectable treatment is remarkable. With about two and a half million treatments performed in 2008, the Botox market is certainly big enough to share, but until now there have been no competitors approved for marketing in the United States for cosmetic applications.
That may change in the upcoming year as a new botulinum toxin A injection may receive Food and Drug Administration (FDA) approval to be marketed for cosmetic applications under the trade name Reloxin. In supporting trials, Reloxin has shown a similar functionality to Botox. The two products have not been compared head-to-head to determine their relative safety and effectiveness, but it is likely they will be similar. At most, one might expect a variation similar to that between Juvéderm and Restylane, where each shows slight benefits over the other for certain applications, and which one a cosmetic surgeon uses depends on his personal preference.
New York cosmetic surgeon Dr. George Lefkovits will evaluate Reloxin, and will provide it to his patients if it seems to offer significant benefits.